Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Health people aged between 18 and 45 years.~2. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations.~3. Able to comply with the requests of the study.~4. Written informed consent obtained from the participants.~5. Axillary temperature not higher than 37.0°C~6. Men, or non-pregnant women verified by a urine pregnancy test.~Exclusion criteria:~1. Pregnant or breastfeeding or plan to be pregnant within 7 months.~2. Use of any investigational product or non-registered product (drug or vaccine) within 30 days preceding the first dose of the study vaccine or plan to use during the study period.~3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment.~4. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine or plan to use within 7 months.~5. Administration of any attenuated live vaccines within 21 days preceding the first dose of the study vaccine or any subunit or inactivated vaccines within 14 days before vaccination.~6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring systemic antibiotics or antiviral treatment within 5 days before vaccination.~7. Having the plan to participate another clinical trial during the study period.~8. Received another HPV vaccine.~9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response).~10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.~11. Asthma that required emergent treatment, hospitalization, oral or intravenous corticosteroid for unstable condition within the past 2 years.~12. Having serious disease of internal medicine, such as hypertension(systolic blood pressure \> 140mmHg or diastolic blood pressure \>90mmHg), cardiac disease, diabetes, hyperthyroidism et al.~13. Diagnosed coagulant function abnormality or blood coagulation disorder. 14) The results of blood routine test and blood biochemical test were abnormal. The grade was 2 or above.~15) Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3 years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3 years.~16) Past or current two-stage affective psychosis, not well controlled in the past 2 years or requiring drugs, or hve a tendency to commit suicide in the past 5 years.~17) Other medical, psychological, social or occupational factors that, according to the investigators' judgment, might affect the individual's ability to obey the protocol or sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HPV Vaccine,135μg/0.5ml (Type: EXPERIMENTAL): Participants in this arm would receive 135μg/0.5ml HPV vaccines
- HPV Vaccine,270μg/1.0ml (Type: EXPERIMENTAL): Participants in this arm would receive 270μg/1.0ml HPV vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete